Cost-effectiveness analysis of the first‐line EGFR‐TKIs in patients with advanced EGFR-mutated non-small-cell lung cancer

  1. Aguilar-Serra, J.
  2. Gimeno-Ballester, V.
  3. Pastor-Clerigues, A.
  4. Milara, J.
  5. Trigo-Vicente, C.
  6. Cortijo, J.
Revista:
Expert Review of Pharmacoeconomics and Outcomes Research

ISSN: 1744-8379,  1473-7167

Ano de publicación: 2022

Volume: 22

Número: 4

Páxinas: 637-646

Tipo: Artigo

DOI: 10.1080/14737167.2022.1987220 GOOGLE SCHOLAR
Fonte de datos: Scopus